Cutler Group LP Red Hill Biopharma Ltd. Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.63 - $2.58 $126 - $516	-200 Closed	0 $0
Q1 2022 Apr 14, 2022	SELL	$1.65 - $3.12 $9,405 - $17,784	-5,700 Reduced 96.61%	200 $0
Q4 2021 Jan 18, 2022	BUY	$2.31 - $5.85 $4,851 - $12,285	2,100 Added 55.26%	5,900 $15,000
Q3 2021 Oct 26, 2021	BUY	$4.55 - $10.36 $17,290 - $39,368	3,800 New	3,800 $17,000
Q2 2021 Jul 19, 2021	SELL	$5.98 - $7.51 $1,196 - $1,502	-200 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$6.98 - $11.29 $9,772 - $15,805	-1,400 Reduced 87.5%	200 $1,000
Q3 2020 Oct 27, 2020	SELL	$6.34 - $10.83 $1,902 - $3,249	-300 Reduced 15.79%	1,600 $16,000
Q2 2020 Jul 22, 2020	SELL	$4.6 - $8.6 $2,520 - $4,712	-548 Reduced 22.39%	1,900 $12,000
Q1 2020 May 07, 2020	BUY	$3.51 - $6.17 $3,327 - $5,849	948 Added 63.2%	2,448 $11,000
Q4 2019 Feb 06, 2020	BUY	$5.76 - $7.35 $1,152 - $1,470	200 Added 15.38%	1,500 $9,000
Q3 2019 Oct 28, 2019	BUY	$6.46 - $8.37 $6,460 - $8,370	1,000 Added 333.33%	1,300 $9,000
Q3 2018 Nov 07, 2018	BUY	$6.0 - $11.35 $1,800 - $3,405	300 New	300 $2,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $415M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.